Novo Nordisk held its investor day in London, outlining its strategy for growth after its key obesity drugs lose patent protection. Despite plans for multiple new blockbusters and expansion into heart and liver disease treatments, analysts were unimpressed by the lack of new data and bold guidance. Deutsche Bank maintained a sell rating and lowered its price target, while Citi stayed neutral, noting the company's growth targets merely meet market expectations. Investors are waiting for more concrete results and potential acquisitions to boost confidence.
Novo Nordisk's investor day in London did not spark enthusiasm among analysts, and this sentiment is mirrored in its stock performance on Pluang. As of Sep 22, 2026 18:51 WIB, Novo Nordisk (NVO) trades at USD 39.26, down 1.41% for the day, with a market cap of $176.30 billion. Despite a strong dividend yield of 4.51% and a typical hold time of 114 days, the stock faces pressure as investors weigh the company's future growth prospects.
Novo Nordisk CEO Mike Doustdar revealed the company is actively considering mergers and acquisitions to strengthen its position in the competitive weight-loss drug market. He emphasized the company's interest in acquiring or partnering with firms tha...
Biotech stocks and leveraged ETFs were the biggest losers in the market, with Cue Biopharma dropping 23.7% despite positive Phase 2 clinical results. Leveraged ETFs tied to AMD, Strategy, and Novo Nordisk also saw sharp declines due to their daily-re...
Novo Nordisk's shares fell over 7% after the company announced long-term targets that failed to reassure investors about competition in the weight-loss drug market. The Danish drugmaker plans to launch multiple blockbuster drugs by 2030 and aims for ...
Novo Nordisk's stock fell 7% following its capital markets day where it outlined a growth plan that aligns with industry peers rather than exceeding them, signaling slower future growth. The company highlighted the upcoming loss of U.S. patent exclus...
Novo, a Danish pharmaceutical company, saw its shares fall up to 7% after announcing plans to launch over five new drugs with blockbuster potential by 2030 and targeting pipeline sales exceeding $23 billion by 2035. The company aims to grow revenue f...
